GLP-R 30mg

This experimental multi-target peptide is a triple receptor agonist designed to activate three key metabolic hormone receptors simultaneously: GIP (glucose-dependent insulinotropic polypeptide), GLP-1 (glucagon-like peptide-1), and glucagon. By combining these three distinct pathways, it works synergistically to regulate metabolism and body composition: • Glycemic & Appetite Control: Like dual-acting precursors, its GIP and GLP-1 activity enhances insulin secretion, slows gastric emptying, and signals satiety to the brain to curb appetite. • Increased Energy Expenditure: The addition of glucagon receptor activation boosts resting metabolic rate, increases energy expenditure, and accelerates fat breakdown (lipolysis) directly in the liver and adipose tissue. Administered as a once-weekly subcutaneous injection, this "triple G" compound has demonstrated unprecedented levels of weight loss and significant reductions in liver fat during Phase 2 clinical studies for obesity and type 2 diabetes.